Launch · Healthcare & Life Sciences

Cent launches with seed funding for early disease detection

By Startup Enthusiast · 6 March 2026

What they do

Cent is a direct-to-consumer platform that uses imaging, biomarkers and AI to detect life-threatening diseases before symptoms appear

It raised undisclosed seed funding from OneFlow Holdings and South Park Commons, and has completed over 1,500 scans since Q1 FY26

India sees 1.5 million new cancer cases yearly, with 70% diagnosed late; Cent's Early Detection Index is 83% versus 15-20% for annual check-ups

Cent launched as a preventive health intelligence company for early detection of life-threatening diseases before symptoms appear.
It raised an undisclosed seed funding from OneFlow Holdings (Shashank's family office) and South Park Commons.
The platform combines advanced imaging, 120+ biomarkers, and AI-powered synthesis to detect cancer, cardiac, neurological, and metabolic risk in asymptomatic people.
Cent operates upstream of traditional physician-led diagnostic pathways, not as a diagnostic chain or wellness service.
It has been operational since Q1 FY26 and completed over 1,500 scans.
26% of scans revealed clinically meaningful findings; 3-4% identified critical conditions needing immediate attention.
The Early Detection Index (EDI) stands at 83%, compared to 15-20% for conventional annual health check-ups.

India records over 1.5 million new cancer cases annually; about 70% are diagnosed at Stage III or IV, with five-year survival rates below 30% for most cancers.
India accounts for over one-fifth of global cardiovascular deaths; average first heart attack at age 53, a decade earlier than in Western populations.
Founder Shashank ND lost three family/close circle members to stage 4 cancer in 2024, motivating the launch.
Recent oncology funding deals include Oncare (Rs 27 crore), 4baseCare (Rs 90 crore), Everhope Oncology ($10M seed), and MOC Cancer Care & Research Centre ($18M).

Cent is a direct-to-consumer platform combining advanced imaging, 120+ biomarkers, and AI-powered synthesis.
It detects cancer, cardiac, neurological, and metabolic risk in asymptomatic people.
Cent operates upstream of traditional physician-led diagnostic pathways, not as a diagnostic chain or wellness service.
Headquarters: Bengaluru.
Operational since Q1 FY26; completed over 1,500 scans.
26% of scans revealed clinically meaningful findings; 3-4% identified critical conditions needing immediate attention.
Early Detection Index (EDI) at 83%, compared to 15-20% for conventional annual health check-ups.

On track to complete 50,000 scans this year.
First dedicated centres rolling out from April 2026 across Mumbai, Delhi, Bengaluru, then Pune and Hyderabad.
Long-term ambition: enable 10 million scans and contribute to one million lives saved by 2035.

Product: Direct-to-consumer preventive healthcare platform offering comprehensive diagnostic scanning including whole-body MRI, low-dose CT, DEXA, ECG and biomarker analysis with AI synthesis
Customers: Direct consumers seeking early disease detection and preventive health intelligence
How it makes money: Direct-to-consumer subscription model for preventive health screening
What sets it apart: AI-led early disease detection focused on identifying cancer, cardiac and metabolic diseases at early stages before symptoms
Operations: Operational across 15 cities with Delhi-NCR expansion including first clinical Prevention Centre in Gurugram